Zobrazeno 1 - 10
of 437
pro vyhledávání: '"P E Postmus"'
Autor:
Jincey D. Sriram, Irma van de Beek, Paul C. Johannesma, Michiel H. van Werkum, Tijmen J. W. T. van der Wel, Elise M. Wessels, Hans J. J. P. Gille, Arjan C. Houweling, Pieter E. Postmus, Hans J. M. Smit
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Birt-Hogg-Dubé syndrome (BHD) is an inherited disease caused by pathogenic variants in the FLCN gene. One of the characteristics is the increased risk for spontaneous pneumothorax, likely due to the presence of pulmonary cysts ma
Externí odkaz:
https://doaj.org/article/f65c31c8c14841f3b507b58dca520cd2
Autor:
Liesbeth M. Hondelink, MD, Merel Jebbink, MD, Jan H. von der Thüsen, MD, PhD, Danielle Cohen, MD, PhD, Hendrikus J. Dubbink, PhD, Marthe S. Paats, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Adrianus J. de Langen, MD, PhD, Mirjam C. Boelens, PhD, Egbert F. Smit, MD, PhD, Pieter E. Postmus, MD, PhD, Tom van Wezel, PhD, Kim Monkhorst, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 12, Pp 100252- (2021)
Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important—and complex. Clear guidelines for analyses of these resistance mechanisms are
Externí odkaz:
https://doaj.org/article/15653a46b49e44dca1398d582c62eabe
Autor:
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E. Postmus, Jaafar Bennouna, Jürgen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Denis Talbot, Ramaswamy Govindan, Teng Jin Ong
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Background: The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially, followed by
Externí odkaz:
https://doaj.org/article/559690e73ee44470a728f1e9dd145ed5
Autor:
Marloes A Smit, Mark WH Philipsen, Pieter E Postmus, Hein Putter, Rob AEM Tollenaar, Danielle Cohen, Wilma E Mesker
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss , Pp 100247- (2020)
Objectives: The tumor-stroma ratio (TSR) is based on the relative amount of stroma in the primary tumor and has proven to be an independent prognostic factor in various solid tumors. The prognosis of patients and adjuvant treatment decision making in
Externí odkaz:
https://doaj.org/article/31d903b64c484d2b88bfc184efc99696
Autor:
Paul C Johannesma, Irma van de Beek, Tijmen J W T van der Wel, Rinze Reinhard, Lawrence Rozendaal, Theo M Starink, Jan Hein T M van Waesberghe, Simon Horenblas, Hans J J P Gille, Marianne A Jonker, Hanne E J Meijers-Heijboer, Pieter E Postmus, Arjan C Houweling, Jeroen R A van Moorselaar
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0212952 (2019)
Birt-Hogg-Dubé syndrome is associated with an increased risk for renal cell carcinoma. Surveillance is recommended, but the optimal imaging method and screening interval remain to be defined. The main aim of our study was to evaluate the outcomes of
Externí odkaz:
https://doaj.org/article/e061467c213648bc94569e95baa4bfc1
Autor:
B P Hoppe, D Schippers, W Thijs, F M Schramel, S A Smulders, J W K Van Den Berg, W J Blox, H J Smit, M Nagtegaal, L Kroft, L Stoger, F Baas, C Van Asperen, C Klop, P E Postmus
Publikováno v:
01.01 - Clinical problems - no related to asthma or COPD.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c83b8716f9c2d0d5cdb3025eef6dd2a
https://doi.org/10.1183/13993003.congress-2022.3442
https://doi.org/10.1183/13993003.congress-2022.3442
Autor:
Marleen J. ter Avest, Romane M. Schook, Lyan G. Koudstaal, Katrien Grünberg, Marinus A. Paul, Egbert F. Smit, Pieter E. Postmus
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 1, Pp 122-125 (2014)
Background: The finding of a renal mass on imaging is suggestive of metastatic non-small cell lung cancer in the presence of a lung tumor but can also have another origin. Case Report: We describe the case of a patient diagnosed with stage IV lung ca
Externí odkaz:
https://doaj.org/article/d9bf80412b8e4f848a5c74438cc7c641
Autor:
D. Kramer, F. B. Thunnissen, M. I. Gallegos-Ruiz, E. F. Smit, P. E. Postmus, C. J. L. M. Meijer, P.J.F. Snijders, D. A. M. Heideman
Publikováno v:
Cellular Oncology, Vol 31, Iss 3, Pp 161-167 (2009)
Background: Increasing evidence points to a negative correlation between K-ras mutations and patient’s response to, or survival benefit after, treatment with EGFR-inhibitors. Therefore, rapid and reliable assays for mutational analysis of the K-ras
Externí odkaz:
https://doaj.org/article/b3dca800acbe4d7e9877d48b2e718323
Autor:
D. A. M. Heideman, F. B. Thunnissen, M. Doeleman, D. Kramer, H. M. Verheul, E. F. Smit, P. E. Postmus, C. J. L. M. Meijer, G.A. Meijer, P. J. F. Snijders
Publikováno v:
Cellular Oncology, Vol 31, Iss 5, Pp 329-333 (2009)
Background: Increasing data from clinical trials support EGFR and K-ras mutation status as predictive markers of tumour response to EGFR-targeted therapies. Consequently, rapid and reliable mutation screening assays are demanded to guide rational use
Externí odkaz:
https://doaj.org/article/0ea96d7979ce4bb1a0a7eaa416f018b2